Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

Focal Glomerulosclerosis Clinical Trial

Official title: Tacrolimus Treatment of Patients With Idiopathic Focal Segmental

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to assess the efficacy of Tacrolimus Treatment of patients with idiopathic focal segmental glomerulosclerosis.

Clinical Trial Description

Primary FSGS is a leading cause of end stage renal disease in adults, with complete loss of kidney function in 50% of patients over 10 years. Steroids, which are currently used to treat the disease, are effective in part of patients. Over the past decade, a number of studies have reported therapeutic efficacy for treatment with Cyclosporine-A (CSA) in patients with FSGS. Recent studies suggest that immunosuppressive therapy targeted against the calcineurin pathway of T-helper cells, for example, tacrolimus, may be effective in the treatment of primary FSGS. The experience with Tacrolimus (FK506) in the treatment of patients with FSGS has been limited to uncontrolled trials in adult patients. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Focal Glomerulosclerosis
• Glomerulosclerosis, Focal Segmental

• NCT number: NCT00302536
• Study type: Interventional
• Source: Nanjing University School of Medicine
• Status: Withdrawn
• Phase: N/A
• Start date: March 2006
• Completion date: September 2010